Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial
-
Published:2024-05
Issue:3
Volume:25
Page:280-283
-
ISSN:1525-7304
-
Container-title:Clinical Lung Cancer
-
language:en
-
Short-container-title:Clinical Lung Cancer
Author:
Matsubara Taichi,
Yamaguchi MasafumiORCID,
Shimokawa MototsuguORCID,
Okamoto Isamu
Reference8 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018
2. Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010;Okami;J Thorac Oncol,2019
3. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial;Felip;Lancet (London, England),2021
4. Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial;Okamoto;JAMA Oncol,2020
5. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies;Nosaki;Lung Cancer,2019